Acute myeloid leukemia: open trials in Norway

13 open trials have a site in Norway. Registry data; only the trial team decides who can take part.

NCT07223814
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Trial Treatment · Phase 3 · Stichting Hemato-Oncologie voor Volwassenen Nederland
Helse Bergen HF, Bergen · Oslo Universitetssykehus HF, Oslo · Helse Stavanger HF, Stavanger · Universitetssykehuset Nord-Norge HF, Tromsoe · St. Olavs hospital HF, Trondheim
Registry updated 2026-11-06
NCT04628026
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
Trial Treatment · Phase 3 · University of Ulm
Haukeland University Hospital, Bergen · Oslo University Hospital, Oslo · Stavanger Univ. Hosp.-Rogaland Hosp., Stavanger · University Hospital of North Norway, Tromso · St Olavs Hospital, Trondheim
Registry updated 2026-11-03
2024-512753-24-00
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.
Trial Treatment · Phase 3 · Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Helse Bergen HF, Bergen · Oslo University Hospital HF, Oslo · Universitetssykehuset Nord-Norge HF, Tromsoe · St. Olavs hospital HF, Trondheim
Registry updated 2026-10-21
2023-504999-25-00
CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML)
Trial Treatment · Phase 3 · Prinses Maxima Centrum voor Kinderoncologie B.V.
Helse Bergen HF, Bergen · Oslo University Hospital HF, Oslo · Universitetssykehuset Nord-Norge HF, Tromsoe · St. Olavs hospital HF, Trondheim
Registry updated 2026-09-23
NCT04996875
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Trial Treatment · Phase 2 · Cogent Biosciences, Inc.
Oslo University Hospital, Oslo
Registry updated 2026-09-15
NCT06652438
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Trial Treatment · Phase 3 · Stichting Hemato-Oncologie voor Volwassenen Nederland
Helse Bergen HF, Bergen · Vestre Viken HF, Drammen · Akershus University Hospital, Loerenskog · Oslo University Hospital HF, Oslo · Helse Stavanger HF, Stavanger · Universitetssykehuset Nord-Norge HF, Tromsoe · St. Olavs hospital HF, Trondheim
Registry updated 2026-09-02
NCT07075016
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Trial Treatment · Phase 3 · Stichting Hemato-Oncologie voor Volwassenen Nederland
NO-Bergen-HELSEBERGEN, Bergen · NO-Oslo-OSLOUH, Oslo · NO-Tromsø-NORTHNOORWEGEN, Tromsø · NO-Trondheim-STOLAV, Trondheim
Registry updated 2025-08-19
NCT06262438
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
Trial Treatment · Phase 2 · Princess Maxima Center for Pediatric Oncology
Helse Bergen HF, Bergen · Oslo University Hospital HF, Oslo · Universitetssykehuset Nord-Norge HF, Tromsoe · St. Olavs hospital HF, Trondheim
Registry updated 2025-08-05
NCT06199557
A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients
Trial Treatment · Phase 1/2 · Haukeland University Hospital
Helse Bergen HF, Bergen · St. Olavs hospital HF, Trondheim
Registry updated 2025-06-29
NCT05477589
Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML
Trial Treatment · Phase 3 · Vastra Gotaland Region
Department of Pediatric Hematology and Oncology, Oslo University HospitalOslo University Hospital, Oslo
Registry updated 2024-12-19
NCT01828489
NOPHO-DBH AML 2012 Protocol: Research study for treatment of children and adolescents with acute myeloid leukemia 0-18 years
Trial Treatment · Phase 3 · Vaestra Goetalandsregionen
Helse Bergen HF, Bergen · Oslo University Hospital HF, Oslo · Universitetssykehuset Nord-Norge HF, Tromsoe · St. Olavs hospital HF, Trondheim
Registry updated 2024-11-22
NCT05431257
Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling
Trial Treatment · Phase 2 · Copenhagen University Hospital, Rigshospitalet
Helse Bergen HF, Bergen · Helse Stavanger HF, Stavanger · Universitetssykehuset Nord-Norge HF, Tromsoe · St. Olavs hospital HF, Trondheim
Registry updated 2022-06-24
NCT05025098
Precision Therapy Versus Standard Therapy in AML and MDS in Elderly
Trial Treatment · Phase 2 · University Hospital, Akershus
Akershus universitetssykehus, Lørenskog
Registry updated 2021-08-27

All Acute myeloid leukemia trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error